Novo Nordisk A/S ADR | Mutual Funds
Mutual Funds that own Novo Nordisk A/S ADR
Loomis Sayles Growth Fund
5,066,842
0.27%
-283,179
2.87%
07/31/2018
BlackRock Equity Dividend Fund
3,220,219
0.17%
-35,164
0.73%
07/31/2018
AST Loomis Sayles Large Cap Growth Portfolio
1,788,625
0.09%
-54,688
2.82%
03/29/2018
BlackRock Health Sciences Opportunities Portfolio
1,452,556
0.08%
-305,144
1%
06/29/2018
1,287,757
0.07%
88,268
1.02%
03/31/2018
Eaton Vance Tax Managed Growth Portfolio
1,283,586
0.07%
12,250
0.34%
06/30/2018
Columbia Variable - Loomis Sayles Growth Fund
1,263,039
0.07%
-7,211
2.75%
03/31/2018
USAA Growth Fund
1,169,417
0.06%
-16,028
1.83%
06/30/2018
1,117,386
0.06%
134,009
2.76%
07/31/2018
Fidelity Low Priced Stock Fund
1,078,770
0.06%
-21,230
0.15%
04/30/2018
| Address |
Novo Allé
Bagsværd CR 2880
Denmark
|
|
Employees
|
- |
| Website |
http://www.novonordisk.com |
| Updated |
07/08/2019 |
| Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. |
